Anaplastic Thyroid Carcinoma: Expression Profile of Targets for Therapy Offers New Insights for Disease Treatment

BackgroundAnaplastic thyroid cancer is an endocrine malignancy. Its rare and rapidly lethal disease course has made it challenging to study. Little is known regarding the expression by anaplastic tumors of molecular targets for new human anticancer agents that have been studied in the preclinical or clinical setting. The objective of this work was to evaluate the expression profile of anaplastic thyroid tumors for molecular targets for treatment.MethodsOf the 94 cases of anaplastic thyroid cancers diagnosed and treated in British Columbia, Canada over a 20-year period (1984–2004), 32 cases (34%) had adequate archival tissue available for evaluation. A tissue microarray was constructed from these anaplastic thyroid tumors and immunohistochemistry was utilized to evaluate expression of 31 molecular markers. The markers evaluated were: epidermal growth factor receptor (EGFR), HER2, HER3, HER4, ER, PR, uPA-R, clusterin, E-cadherin, β-catenin, AMF-R, c-kit, VEGF, ILK, aurora A, aurora B, aurora C, RET, CA-IX, IGF1-R, p53, MDM2, p21, Bcl-2, cyclin D1, cyclin E, p27, calcitonin, MIB-1, TTF-1, and thyroglobulin.ResultsA single tumor with strong calcitonin expression was identified as a poorly differentiated medullary carcinoma and excluded from the study cohort. The mean age of the anaplastic cohort was 66 years; 16 patients (51%) were females, and the median patient survival was 23 weeks. A wide range in molecular marker expression was observed by the anaplastic thyroid cancer tumors (0–100%). The therapeutic targets most frequently and most strongly overexpressed by the anaplastic tumors were: β-catenin (41%), aurora A (41%), cyclin E (67%), cyclin D1 (77%), and EGFR (84%).ConclusionsAnaplastic thyroid tumors exhibit considerable derangement of their cell cycle and multiple signal transduction pathways that leads to uncontrolled cellular proliferation and the development of genomic instability. This report is the first to comprehensively evaluate a panel of molecular targets for therapy of anaplastic thyroid cancer and supports the development of clinical trials with agents such as cetuximab, small-molecule tyrosine kinase inhibitors, and aurora kinase inhibitors, which may offer new hope for individuals diagnosed with this fatal thyroid malignancy.

[1]  M. Schlumberger,et al.  Anaplastic Thyroid Carcinoma , 2003 .

[2]  J. Baselga,et al.  Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Lam,et al.  Anaplastic carcinoma of the thyroid. , 1999, American journal of surgery.

[4]  C Blake Gilks,et al.  Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. , 2002, American journal of clinical pathology.

[5]  M. Shah,et al.  Targeting the cell cycle: a new approach to cancer therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  N. Georgopapadakou,et al.  Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[7]  R. Comis,et al.  The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. , 2005, The oncologist.

[8]  M. Nakashima,et al.  The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. , 2003, The Journal of clinical endocrinology and metabolism.

[9]  L. Hofbauer,et al.  Paneling human thyroid cancer cell lines for candidate proteins for targeted anti‐angiogenic therapy , 2006, Journal of cellular biochemistry.

[10]  P. Chieffi,et al.  0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(2):928–935 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/jc.2004-1518 Aurora B Overexpression Associates with the Thyroid Carcinoma Undifferentiated Phe , 2004 .

[11]  A. Bauer,et al.  Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes , 2005, Cancer Chemotherapy and Pharmacology.

[12]  T. Fojo,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Effects of p53-Expressing Adenovirus on the Chemosensitivity and Differentiation of Anaplastic , 2022 .

[13]  L. Ghoda,et al.  Activities of purine-metabolizing enzymes in human colon carcinoma cell lines and xenograft tumors. , 1981, Biochemical pharmacology.

[14]  J. Rosai.  Immunohistochemical Markers of Thyroid Tumors Significance and Diagnostic Applications , 2003, Tumori.

[15]  Kunihiko Ito,et al.  Study of cell kinetics in anaplastic thyroid carcinoma transplanted to nude mice , 1989, Journal of surgical oncology.

[16]  C. Visintin,et al.  Aurora A and B kinases as targets for cancer: will they be selective for tumors? , 2006, Expert review of anticancer therapy.

[17]  A. Shaha,et al.  Anaplastic Thyroid Carcinoma: Biology, Pathogenesis, Prognostic Factors, and Treatment Approaches , 2006, Annals of Surgical Oncology.

[18]  N. Konishi,et al.  Immunohistochemical analysis of estrogen receptors in 313 paraffin section cases of human thyroid tissue. , 1993, Oncology.

[19]  S. Filetti,et al.  p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells , 1997, Oncogene.

[20]  M. Saji,et al.  Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. , 2002, Thyroid : official journal of the American Thyroid Association.

[21]  E. Kebebew,et al.  Anaplastic thyroid carcinoma , 2005, Cancer.

[22]  P. Kristjansen,et al.  Antitumor efficacy of a urokinase activation–dependent anthrax toxin , 2006, Molecular Cancer Therapeutics.

[23]  T. Kosaka,et al.  Correlation of DNA ploidy and clinical outcome in borrmann type 4 gastric carcinoma , 1989, Journal of surgical oncology.

[24]  J. Schellens,et al.  Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). , 2005, The oncologist.

[25]  G. Gray,et al.  Targeted therapy for cancer: the HER-2/neu and Herceptin story. , 2003, Clinical leadership & management review : the journal of CLMA.

[26]  David Bebbington,et al.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo , 2004, Nature Medicine.

[27]  S. Wiseman,et al.  Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. , 2006, American journal of surgery.

[28]  B. Westermark,et al.  The molecular biology of the human anaplastic thyroid carcinoma cell. , 1991, Thyroidology.

[29]  B. O'neill,et al.  Anaplastic (undifferentiated) thyroid cancer: improved insight and therapeutic strategy into a highly aggressive disease , 2005, The Journal of Laryngology & Otology.

[30]  Ash A. Alizadeh,et al.  Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. , 2002, The American journal of pathology.

[31]  H. Buhr,et al.  Immunohistochemical reclassification of anaplastic carcinoma reveals small and giant cell lymphoma , 1990, World Journal of Surgery.

[32]  N. Ordóñez,et al.  Anaplastic carcinoma of the thyroid: A clinicopathologic study of 121 cases , 1990, Cancer.

[33]  K. Ain,et al.  Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro. , 2004, The Journal of clinical endocrinology and metabolism.

[34]  C. Arteaga,et al.  HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. , 2002, Seminars in oncology.

[35]  M. Mandal,et al.  Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT‐11 , 2006, Head & neck.

[36]  M. Mandal,et al.  Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788 , 2005, Molecular Cancer Therapeutics.

[37]  B Nebiyou Bekele,et al.  Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice , 2006, Clinical Cancer Research.

[38]  S. Wiseman,et al.  Anaplastic transformation of thyroid cancer: Review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy , 2003, Head & neck.

[39]  Y. Nobuhara,et al.  Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines , 2005, British Journal of Cancer.

[40]  L. Saltz.  Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity? , 2005, Clinical colorectal cancer.

[41]  D. Mason,et al.  The value of immunocytochemical methods in the differential diagnosis of anaplastic thyroid tumours. , 1985, British Journal of Cancer.

[42]  Mitch Dowsett,et al.  Proliferation marker Ki-67 in early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  G. Thompson,et al.  Anaplastic thyroid carcinoma: a 50-year experience at a single institution. , 2001, Surgery.

[44]  C. Blanke,et al.  Gastrointestinal stromal tumors and the evolution of targeted therapy. , 2005, Clinical advances in hematology & oncology : H&O.

[45]  A. J. Garrett,et al.  CANCER XENOGRAFTS IN NUDE MICE , 1976, The Lancet.

[46]  R. Lloyd,et al.  The Role of Cell Cycle Regulatory Protein, Cyclin D1, in the Progression of Thyroid Cancer , 2000, Modern Pathology.

[47]  L. Grimelius,et al.  Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery , 2002, British Journal of Cancer.

[48]  B. Brandt,et al.  The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. , 2005, Histology and histopathology.

[49]  L. Saltz,et al.  Antibody-based therapies for colorectal cancer. , 2005, The oncologist.

[50]  B. Westermark,et al.  Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. , 2000, Experimental cell research.

[51]  R. Kerbel,et al.  Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. , 2002, Cancer research.

[52]  G. Mikuz,et al.  Her2/neu expression in poorly-differentiated and anaplastic thyroid carcinomas. , 2003, Anticancer research.

[53]  K. Ain.  Anaplastic thyroid carcinoma: a therapeutic challenge. , 1999, Seminars in surgical oncology.

[54]  E. Baudin,et al.  Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. , 2004, International Journal of Radiation Oncology, Biology, Physics.

[55]  K. Schmid,et al.  Epidermal Growth Factor Receptor as a Novel Therapeutic Target in Anaplastic Thyroid Carcinomas , 2004, Annals of the New York Academy of Sciences.

[56]  Yutaka Yamamoto,et al.  Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells , 2006, Cancer Chemotherapy and Pharmacology.

[57]  L. Bañez,et al.  VEGF inhibitors in cancer therapy. , 2006, Current pharmaceutical design.

[58]  J. Buolamwini,et al.  Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. , 2005, Current cancer drug targets.

[59]  K. Lam,et al.  Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. , 2000, Annals of surgery.

[60]  G. Chiappetta,et al.  RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[61]  Toshihiro Tanaka,et al.  Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes. , 2004, Endocrine-related cancer.

[62]  N. Ordóñez,et al.  Anaplastic thyroid carcinoma. Immunocytochemical study of 32 cases. , 1991, American journal of clinical pathology.

[63]  A. El‐Naggar,et al.  Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer , 2004, Clinical Cancer Research.

[64]  P. Wollan,et al.  Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[65]  J. Manfredi,et al.  Multiple roles of the tumor suppressor p53 , 2002, Current opinion in oncology.

[66]  G. Mills,et al.  Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer , 2005, Molecular Cancer Therapeutics.

[67]  D. Grimm,et al.  Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. , 2004, Endocrinology.

[68]  R. Lauro,et al.  Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. , 1996, Cancer research.

[69]  A. Belfiore,et al.  The IGF system in thyroid cancer: new concepts , 2001, Molecular pathology : MP.

[70]  G. Brabant,et al.  E-cadherin: a differentiation marker in thyroid malignancies. , 1993, Cancer research.

[71]  Y. Miyoshi,et al.  uPA receptor expression in benign and malignant thyroid tumors. , 2002, Anticancer research.